ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CSF α-synuclein seed amplification assay positivity identifies a distinct soluble amyloid-β profile linked to fibrillar amyloid burden and structural neurodegeneration.Research square · 2026Article
- Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionBrain atrophy patterns in Alzheimer's disease (AD) are well established, however, the contribution of alpha-synuclein (α-syn) copathology to these patterns remains unclear. This study investigates magnetic resonance imaging (MRI) -based atrophy patterns in AD patients with α-syn copathology.
methodsWe study two independent cohorts: Hospital Clinic Barcelona (
resultsCompared to CTR, both AD-αSAA- and AD-αSAA+ showed widespread cortical thinning. Direct comparison of AD-αSAA+ versus AD-αSAA- revealed differential involvement of insular, entorhinal, lateral temporal, pre and postcentral gyrus, frontal cortices, and amygdala, although with minimum size effect. DISCUSSION: α-Syn copathology was associated with more extensive and pronounced atrophy, especially in frontal, lateral temporal, entorhinal, and amygdalar regions. This suggests that α-syn is associated with greater neurodegeneration beyond typical AD patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.